Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of EPX-100 in Healthy Subjects
NCT04069689Phase 1Completed
- Sponsor
- Epygenix Therapeutics
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Dravet syndrome comparing EPX-100 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 21 days, Serial ECGs - QTcF Interval at 21 days and 1 more. Started Aug 2019; status: completed.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT04069689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069689.